Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease (Q36050347)

11 August 2017

1 reference

title

Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease (English)

1 reference

11 August 2017

1 reference

Bates KA

1

1 reference

11 August 2017

Harvey AR

series ordinal

2

1 reference

11 August 2017

Carruthers M

series ordinal

3

1 reference

11 August 2017

Martins RN

series ordinal

4

1 reference

11 August 2017

publication date

1 February 2005

1 reference

Cellular and Molecular Life Sciences

11 August 2017

published in

1 reference

11 August 2017

volume

62

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

281-292

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-004-4383-1

11 August 2017

exact match

0 references

cites work

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.

1 reference

12 December 2020

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

1 reference

12 December 2020

Edoxaban versus warfarin in patients with atrial fibrillation

1 reference

12 December 2020

Rates of hemorrhage during warfarin therapy for atrial fibrillation

1 reference

12 December 2020

Idarucizumab for Dabigatran Reversal

1 reference

12 December 2020

A specific antidote for dabigatran: functional and structural characterization

1 reference

12 December 2020

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

1 reference

12 December 2020

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

1 reference

12 December 2020

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

1 reference

12 December 2020

Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control

1 reference

12 December 2020

Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.

1 reference

12 December 2020

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

12 December 2020

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

1 reference

12 December 2020

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

1 reference

12 December 2020

Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent

1 reference

12 December 2020

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

1 reference

12 December 2020

Apixaban versus warfarin in patients with atrial fibrillation

1 reference

12 December 2020

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

1 reference

12 December 2020

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

1 reference

12 December 2020

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S00018-004-4383-1

Identifiers

DOI

1 reference

11 August 2017

1 reference